Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 11, 2012, Pages 1821-1830

  Pfeifer, Sabine ^a   Schreder, Martin ^a   Bolomsky, Arnold ^a   Graffi, Sebastian ^a   Fuchs, Dietmar ^b   Sahota, Surinder S ^c   Ludwig, Heinz ^a   Zojer, Niklas ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Immunosuppression; Indoleamine 2,3 dioxygenase; Interferon y; Mesenchymal stromal cells; Myeloma tumor niche

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; SCATTER FACTOR; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; ENZYME INDUCTION; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STROMA CELL; TUMOR MICROENVIRONMENT;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INDOLES; INTERFERON-GAMMA; MESENCHYMAL STROMAL CELLS; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY, ULTRAVIOLET; THIOHYDANTOINS; TRYPTOPHAN; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870417566     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1259-2     Document Type: Article

References (32)

1. Bonanno G, Corallo M, Mariotti A, Di Maggio A, Procoli A, De Rosa L, Pierelli L, Majolino I, Leone G, De Cristofaro R, Rutella S (2008) Indoleamine 2,3-Dioxygenase (IDO) is expressed by multiple myeloma plasma cells and promotes the differentiation of regulatory T-cells: investigations into the role of hepatocyte growth factor. Blood (ASH Annual Meeting Abstracts) 112:1680
2. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T-cells. Clin Cancer Res 12: 1144-1151 (Pubitemid 43342502)
3. Brunner M (1973) Regulation of DNA synthesis by amino acid limitation. Cancer Res 33: 29-32
4. Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R, Valk PJ, Lowenberg B, Ossenkoppele GJ (2008) High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 93: 1894-1898
5. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Reme T, Bourin P (2007) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21: 1079-1088 (Pubitemid 46672085)
6. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24: 986-991 (Pubitemid 44464731)
7. Hayaishi O, Yoshida R (1978) Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide. Ciba Found Symp 65: 199-203
8. Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, Marculescu R, Le T, Mannhalter C, Gaiger A, Stilgenbauer S, Dohner H, Fonatsch C, Jager U (2004) High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 18: 756-762 (Pubitemid 38500194)
9. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O, Kikkawa F (2006) Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95: 1555-1561 (Pubitemid 44863359)
10. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F (2008) Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14: 2310-2317 (Pubitemid 351551062)
11. Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S (2004) Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 19: 319-326 (Pubitemid 38338742)
12. Jurgens B, Hainz U, Fuchs D, Felzmann T, Heitger A (2009) Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T-cells. Blood 114: 3235-3243
13. Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S (2003) Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. J Exp Ther Oncol 3: 336-345 (Pubitemid 38056112)
14. Kuang DM, Zhao Q, Xu J, Yun JP, Wu C, Zheng L (2008) Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T-cells through oxygen-dependent pathways. J Immunol 181: 3089-3098
15. Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, Gutterman JU (1986) Phase I study of i.v. administered recombinant gamma interferon in cancer patients. Cancer Treat Rep 70: 1357-1364 (Pubitemid 17005112)
16. Maby-El Hajjami H, Ame-Thomas P, Pangault C, Tribut O, DeVos J, Jean R, Bescher N, Monvoisin C, Dulong J, Lamy T, Fest T, Tarte K (2009) Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res 69: 3228-3237
17. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619-4621 (Pubitemid 38745993)
18. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E, Campana D (2003) Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 120: 846-849 (Pubitemid 36315109)
19. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319 (Pubitemid 40460560)
20. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193 (Pubitemid 28406294)
21. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T-cell proliferation by macrophage tryptophan catabolism. J Exp Med 189: 1363-1372 (Pubitemid 29227522)
22. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12: 870-878
23. Pfefferkorn ER (1984) Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 81: 908-912 (Pubitemid 14197611)
24. Portier M, Zhang XG, Caron E, Lu ZY, Bataille R, Klein B (1993) gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 81: 3076-3082 (Pubitemid 23162128)
25. Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU (1988) Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macro-globulinemia. Am J Hematol 29: 1-4
26. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W (2007) Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with longterm survival of patients with renal cell carcinoma. Clin Cancer Res 13: 6993-7002 (Pubitemid 350276880)
27. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ (2002) Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 20: 530-541 (Pubitemid 35463066)
28. Sun J, Yu J, Li H, Yang L, Wei F, Yu W, Liu J, Ren X (2011) Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T-cells and increases proportion of Treg cells. J Exp Clin Cancer Res 30:82
29. Traxlmayr MW, Wesch D, Dohnal AM, Funovics P, Fischer MB, Kabelitz D, Felzmann T (2010) Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother 33: 40-52
30. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274 (Pubitemid 37279849)
31. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43: 2424-2426 (Pubitemid 28022985)
32. Woolley PV, Dion RL, Bono VH Jr (1974) Effects of tryptophan deprivation on L1210 cells in culture. Cancer Res 34: 1010-1014